𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A humanized Anti-c-erbB-2 monoclonal antibody for the treatment of breast cancer

✍ Scribed by Yutaka Tokuda; Akira Okumura; Masatoshi Ohta; Mitsuhiro Kubota; Yasuyuki Ohnishi; Kazuo Shmamura; Masumi Yoshimura; Yoshito Ueyama; Norikazu Tamaoki; Tomoo Tajima

Publisher
Springer Japan
Year
1997
Tongue
English
Weight
302 KB
Volume
4
Category
Article
ISSN
1340-6868

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Bispecific monoclonal antibody therapy (
Bispecific monoclonal antibody therapy (anti HER-2/neu Γ— anti CD 64) for human breast cancers that overexpress HER-2/neu
✍ Frank H. Valone; Peter A. Kaufman; Michael W. Fanger; Paul M. Guyre; Clark Sprin πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 184 KB

One of the most critical issues regarding management of early breast cancer is the proper detection and correct estimation of its malignant potential. In recent years, primarily through mammography, the frequency of ductal carcinoma in situ (DCIS) in malignant breast biopsies has increased several f

Tocilizumab, a humanized anti-interleuki
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders
✍ Toshio Tanaka; Keisuke Hagihara; Yoshihito Shima; Masashi Narazaki; Atsushi Ogat πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 197 KB

## Abstract The cytokine interleukin (IL)‐6 has a wide range of biological activities. It contributes to host defense against pathogens by inducing immune responses, hematopoiesis, and acute‐phase reactions. However, dysregulation of IL‐6 production plays a significant pathological role in various

CNTO 859, a humanized anti-tissue factor
CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models
✍ Cam V. Ngo; Kristen Picha; Francis McCabe; Hillary Millar; Richard Tawadros; Sus πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 383 KB πŸ‘ 1 views

## Abstract Thromboembolic complications are frequently associated with advanced cancer. Interestingly, one of the major initiators of blood coagulation, tissue factor (TF), is reported to be overexpressed in several tumor types and can be found on both tumor cells and tumor vasculature. Although t